The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib

BACKGROUND AND AIMS: The multikinase inhibitor sorafenib is the only currently approved drug for the indication of advanced hepatocellular carcinoma (HCC). It provides a limited gain in survival time but is frequently associated with adverse events. We currently lack simple prognostic factors in sor...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Conroy, Guillaume, Salleron, Julia, Belle, Arthur, Bensenane, Mouni, Nani, Abdelbasset, Ayav, Ahmet, Peiffert, Didier, Lopez, Anthony, Baumann, Cédric, Barraud, Hélène, Bronowicki, Jean-Pierre
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2017
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5707066/
https://ncbi.nlm.nih.gov/pubmed/29221172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.21401
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados